Loading
A phase 3 trial testing INCB123667 in ovarian cancer, now recruiting.
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 3 interventional study registered as NCT07214779, led by Incyte with ENGOT Foundation and GOG Foundation, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Planned enrolment is 466 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2028-11-15. No results have been posted on ClinicalTrials.gov.
Shares INCB123667, Incyte, Platinum-resistant ovarian cancer, Ovarian cancer.